3 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Withdrawn 3 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Social Behavior: new trials by email Literature Review of Social Behavior trials Research Report on Social Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation Daratumumab - Allosensitization, Heart Transplant Failure and Rejection | Phase 1 | Withdrawn | Ronald Witteles | 2021-04-01 | 2020-10-28 | |
| tVNS in Children With Prader-Willi Syndrome tVNS - Prader-Willi Syndrome, Social Behavior | Phase 1 / Phase 2 | Withdrawn | Stanford University | 2020-07-01 | 2021-05-06 | |
| Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells Efalizumab - Autoimmune Diseases | Phase 1 / Phase 2 | Withdrawn | University of California, San Francisco | 2008-12-01 | 2013-05-14 |
Rejection, Psychology (2) · Autoimmune Diseases (1) · Prader-Willi Syndrome (1)
Behavior (3) · Abnormalities, Multiple (1) · Chromosome Disorders (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Immune System Diseases (1) · Imprinting Disorders (1) · Intellectual Disability (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1)
daratumumab (1) · efalizumab (1)
Ronald Witteles (1) · Stanford University (1) · University of California, San Francisco (1)
United States (1)
Flavio Vincenti, M.D. (1) · Ronald M Witteles, MD (1)